Back to 
Schonfeld Strategic Advisors LLC
Schonfeld Strategic Advisors LLC
VRAX
2 quarters
Position history for Schonfeld Strategic Advisors LLC's holdings in Virax Biolabs Group Limited
No. Schonfeld Strategic Advisors exited its VRAX (Virax Biolabs Group) position in Q4 2022. Its Q3 2022 13F listed 36,600 shares worth $115,000. Schonfeld Strategic Advisors first reported VRAX in Q3 2022 and held it in 1 quarterly 13F filing.
Final Value
$0
Final Shares
0
Total Value Change
-$115,000
Total Shares Change
-36,600
Quarter-by-Quarter History
Other major holders of VRAX: Legal & General Group Plc, UBS Group AG, Virtu Financial LLC, Millennium Management LLC